LabEx Transimmunom

Chronic inflammation, a condition present in various diseases including those with an immune component, is an important cause of morbidity/mortality in the developed world. A wide range of disorders fall into this disease category. These are rare or common disorders, whose best management requires an integrated approach, tightly linking clinicians from internal medicine or medical specialties to research teams with translational research programs in the field.

The Rationale For TRANSIMMUNOM Stems From Three Main Paradigms:

• Recent progresses in understanding inflammatory and autoimmune diseases.
• The immune system is a complex dynamic system made of a network of specialized cells and molecules.
• Inflammatory and autoimmune diseases are particularly suitable to the development of novel immunotherapies based on either drug, protein or cell intervention.

The Transimmunom Consortium Comprises:

• ​Clinicians with strong research activities, with expertise covering immunopathology and inflammatory diseases, and with major records including pioneering clinical trials,
• Immunologists with expertise in state-of-the-art immune investigations and records in developing novel technologies,
• Scientists with expertise in computer science, bioinformatics, biostatistics, text-mining and data management,
• Three SMEs, ILTOO Pharma, Pharnext and Prediguard, involved in biomarker discovery and biotherapy development.

​Objectives

Our General Objective Is:

to study inflammation and immunopathologies by integrating basic, clinical and information sciences. We aim to break down some artificial boundaries by analyzing important phenotypes that cut across diagnostic groups and reconsider current disease classification schemes. ​

Our Specific Objectives Are:​

• ​​​to cross-phenotype eight inflammatory and autoimmune diseases
• to discover and validate biomarkers and novel therapeutic targets to improve diagnosis and prognosis and treatment
• to improve and develop biotherapies based on this knowledge​